Focus: Vericel is a public biotechnology company headquartered in Burlington, MA specializing in cellular therapy across multiple therapeutic indications including critical limb ischemia, osteonecrosis, and cartilage defects. The company maintains a focused pipeline of autologous cell therapies with advanced clinical programs in Phase 2–3 development.
Profile data last refreshed 27m ago · AI intelligence enriched 3w ago
Stable — net +3 jobs in 30d
16 added, 13 removed. Backfill posture.
Best suited for manufacturing, quality, and commercial-track professionals seeking exposure to cell therapy and public-company execution with acceptable downside risk; less ideal for research-focused scientists or those seeking large team environments.
Help build intelligence for Vericel
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Vericel's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Vericel (VCEL) Could Be 33% Undervalued After Insider Sales Raised Fresh Questions - simplywall.st
Vericel (VCEL) Could Be 33% Undervalued After Insider Sales Raised Fresh Questions simplywall.st
VCEL News | VERICEL CORP (NASDAQ:VCEL) - ChartMill
VCEL News | VERICEL CORP (NASDAQ:VCEL) ChartMill
Vericel Stock Is Up 10%. Here's What This $402,000 Insider Sale Really Suggests - AOL.com
Vericel Stock Is Up 10%. Here's What This $402,000 Insider Sale Really Suggests AOL.com
Vericel (VCEL) Stock Could Be 37.3% Undervalued After Earnings Beat And Fund Buying - simplywall.st
Vericel (VCEL) Stock Could Be 37.3% Undervalued After Earnings Beat And Fund Buying simplywall.st
Vericel (VCEL) Is Up 7.0% After Earnings Beat And Conference Spotlight Has The Bull Case Changed? - simplywall.st
Vericel (VCEL) Is Up 7.0% After Earnings Beat And Conference Spotlight Has The Bull Case Changed? simplywall.st
How to watch Vericel's June 16 Truist MedTech talk online - Stock Titan
How to watch Vericel's June 16 Truist MedTech talk online Stock Titan
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo